Trial Profile
A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia (Non PK Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Oct 2020
Price :
$35
*
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Registrational; Therapeutic Use
- Sponsors Serenity Pharmaceuticals Corporation
- 18 Jul 2012 New trial record